CN117426422A - Formula milk powder with gastrointestinal tract regulating function and preparation method thereof - Google Patents
Formula milk powder with gastrointestinal tract regulating function and preparation method thereof Download PDFInfo
- Publication number
- CN117426422A CN117426422A CN202311445555.2A CN202311445555A CN117426422A CN 117426422 A CN117426422 A CN 117426422A CN 202311445555 A CN202311445555 A CN 202311445555A CN 117426422 A CN117426422 A CN 117426422A
- Authority
- CN
- China
- Prior art keywords
- mass
- parts
- milk powder
- formula
- formula milk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 154
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 117
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 46
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 88
- 239000000203 mixture Substances 0.000 claims abstract description 51
- 239000002994 raw material Substances 0.000 claims abstract description 46
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 34
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 13
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 10
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 10
- 244000197580 Poria cocos Species 0.000 claims description 32
- 241000209140 Triticum Species 0.000 claims description 25
- 235000021307 Triticum Nutrition 0.000 claims description 25
- 235000010755 mineral Nutrition 0.000 claims description 24
- 239000011707 mineral Substances 0.000 claims description 24
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 20
- 102000015636 Oligopeptides Human genes 0.000 claims description 18
- 108010038807 Oligopeptides Proteins 0.000 claims description 18
- 240000000588 Hericium erinaceus Species 0.000 claims description 16
- 235000007328 Hericium erinaceus Nutrition 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 15
- 229930003231 vitamin Natural products 0.000 claims description 15
- 235000013343 vitamin Nutrition 0.000 claims description 15
- 239000011782 vitamin Substances 0.000 claims description 15
- 229940088594 vitamin Drugs 0.000 claims description 15
- 102000007544 Whey Proteins Human genes 0.000 claims description 14
- 108010046377 Whey Proteins Proteins 0.000 claims description 14
- 235000013336 milk Nutrition 0.000 claims description 14
- 239000008267 milk Substances 0.000 claims description 14
- 210000004080 milk Anatomy 0.000 claims description 14
- 235000020185 raw untreated milk Nutrition 0.000 claims description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 12
- 239000011575 calcium Substances 0.000 claims description 12
- 229910052791 calcium Inorganic materials 0.000 claims description 12
- 235000018102 proteins Nutrition 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- 239000005862 Whey Substances 0.000 claims description 11
- 240000008042 Zea mays Species 0.000 claims description 11
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 11
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 11
- 235000005822 corn Nutrition 0.000 claims description 11
- 235000015097 nutrients Nutrition 0.000 claims description 11
- 150000003904 phospholipids Chemical class 0.000 claims description 11
- 235000020183 skimmed milk Nutrition 0.000 claims description 11
- 239000006188 syrup Substances 0.000 claims description 11
- 235000020357 syrup Nutrition 0.000 claims description 11
- 239000006041 probiotic Substances 0.000 claims description 10
- 235000018291 probiotics Nutrition 0.000 claims description 10
- 235000002639 sodium chloride Nutrition 0.000 claims description 10
- 229920001353 Dextrin Polymers 0.000 claims description 9
- 239000004375 Dextrin Substances 0.000 claims description 9
- 229920001202 Inulin Polymers 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 235000014633 carbohydrates Nutrition 0.000 claims description 9
- 235000019425 dextrin Nutrition 0.000 claims description 9
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 9
- 229940029339 inulin Drugs 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 102000010445 Lactoferrin Human genes 0.000 claims description 8
- 108010063045 Lactoferrin Proteins 0.000 claims description 8
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 8
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 8
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 8
- 235000021242 lactoferrin Nutrition 0.000 claims description 8
- 229940078795 lactoferrin Drugs 0.000 claims description 8
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 7
- 244000182216 Mimusops elengi Species 0.000 claims description 7
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 7
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 7
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 235000008476 powdered milk Nutrition 0.000 claims description 3
- 235000021119 whey protein Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 244000241838 Lycium barbarum Species 0.000 claims 1
- 235000015459 Lycium barbarum Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 235000019640 taste Nutrition 0.000 abstract description 10
- 239000000796 flavoring agent Substances 0.000 abstract description 8
- 235000019634 flavors Nutrition 0.000 abstract description 8
- 241001619444 Wolfiporia cocos Species 0.000 abstract 2
- 230000000052 comparative effect Effects 0.000 description 48
- 241000252212 Danio rerio Species 0.000 description 38
- 230000002496 gastric effect Effects 0.000 description 33
- 230000006870 function Effects 0.000 description 21
- 238000011282 treatment Methods 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 210000004877 mucosa Anatomy 0.000 description 10
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 9
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000005176 gastrointestinal motility Effects 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000008439 repair process Effects 0.000 description 7
- 241000186000 Bifidobacterium Species 0.000 description 6
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000007661 gastrointestinal function Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241001672694 Citrus reticulata Species 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 201000006549 dyspepsia Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000008855 peristalsis Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
- 229960004618 prednisone Drugs 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000009854 mucosal lesion Effects 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241000737241 Cocos Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010059186 Early satiety Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 241000634212 Penia Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- -1 flavonoid compounds Chemical class 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 231100001014 gastrointestinal tract lesion Toxicity 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000008944 intestinal immunity Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 description 1
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000000270 postfertilization Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/06—Mixtures of whey with milk products or milk components
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/02—Whey; Whey preparations containing, or treated with, microorganisms or enzymes
- A23C21/026—Whey; Whey preparations containing, or treated with, microorganisms or enzymes containing, or treated only with, lactic acid producing bacteria, bifidobacteria or propionic acid bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/04—Whey; Whey preparations containing non-milk components as source of fats or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/08—Whey; Whey preparations containing other organic additives, e.g. vegetable or animal products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/10—Whey; Whey preparations containing inorganic additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C2240/00—Use or particular additives or ingredients
- A23C2240/15—Use of plant extracts, including purified and isolated derivatives thereof, as ingredient in dairy products
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides formula milk powder with gastrointestinal tract regulating function and a preparation method thereof. The invention provides a formula milk powder with gastrointestinal tract regulating function, wherein the raw materials for preparing the formula milk powder at least comprise a composition with gastrointestinal tract regulating function, and the composition with gastrointestinal tract regulating function at least comprises a dried orange peel extract and a poria cocos extract; based on every 100g of the formula milk powder, the content of protein in the formula milk powder is 16.5-30 g, the content of fat is 1.0-23 g, the content of dietary fiber is 0-7.5 g, and the content of carbohydrate is 50-69 g. By adding the composition with gastrointestinal tract regulating function at least comprising the dried orange peel extract and the poria cocos extract into the formula milk powder, the formula milk powder has the effect of regulating gastrointestinal tract function, and has the characteristics of high safety, small side effect, strong efficacy, good taste and flavor and the like.
Description
Technical Field
The invention relates to formula milk powder with gastrointestinal tract regulating function and a preparation method thereof, and relates to the technical field of foods.
Background
Functional dyspepsia (Functional Dyspepsia, FD) is a digestive system disease with more than one of abdominal pain, early satiety, postprandial discomfort and burning of upper abdomen as main symptoms, and FD is a non-organic disease, but has the characteristics of long disease course and easy repetition, and is one of main gastrointestinal diseases faced by clinicians. The pathogenesis of FD is not clear, but the prior study shows that the FD is related to gastrointestinal motility and sensitivity, brain-intestine axis dysfunction, helicobacter pylori infection, social and psychological factors, intestinal flora, inheritance and other factors, so that the regulation of the gastrointestinal tract function can be used as one of means for preventing and treating FD.
The current food with gastrointestinal tract regulating function is mainly prepared by regulating intestinal flora, protecting gastric mucosa, promoting digestion and the like. The probiotics and part of the traditional Chinese medicines have the well-known benefit of regulating the gastrointestinal flora, and the formula for promoting the gastrointestinal health by taking common food as raw materials and adding homologous components of medicine and food or other nutrition enhancers or probiotic combinations is available. However, the formula of the food is complex, and the ingredients of the traditional Chinese medicinal materials occupy a large amount, so that the taste and flavor of the product are affected.
Disclosure of Invention
The invention provides a formula milk powder with gastrointestinal tract regulating function and a preparation method thereof, wherein the formula milk powder is added with a composition with gastrointestinal tract regulating function, which at least comprises a dried orange peel extract and a poria cocos extract, so that the formula milk powder has the effect of regulating the gastrointestinal tract function, and has the characteristics of high safety, small side effect, strong efficacy, good taste and flavor and the like.
The invention provides a formula milk powder with gastrointestinal tract regulating function, wherein the raw materials for preparing the formula milk powder at least comprise a composition with gastrointestinal tract regulating function, and the composition with gastrointestinal tract regulating function at least comprises a dried orange peel extract and a poria cocos extract;
based on 1000 parts by mass of formula milk powder, the mass parts of the dried orange peel extract in the raw materials for preparing the formula milk powder are 2-50, and the mass parts of the poria cocos extract are 2-50;
based on every 100g of the formula milk powder, the content of protein in the formula milk powder is 16.5-30 g, the content of fat is 1.0-23 g, the content of dietary fiber is 0-7.5 g, and the content of carbohydrate is 50-69 g.
The invention adds tangerine peel extract and Indian buead extract into the preparation raw materials of the formula milk powder, the tangerine peel is the dried mature pericarp of Rutaceae plant (Citrus reticulata Blanco) and cultivated varieties thereof, and is rich in various medicinal active ingredients, such as volatile oils of D-limonene, beta-myrcene, alpha-pinene and the like, flavonoids of hesperidin, neohesperidin, citrus element and the like, and various microelements. Modern pharmacological researches show that the dried orange peel has various pharmacological effects of resisting bacteria, diminishing inflammation, resisting oxidation, promoting digestion, protecting liver, lowering blood pressure and the like, and in particular, polymethoxy flavonoid compounds (nobiletin and hesperetin) in the dried orange peel have obvious digestion promoting capability, and can promote the intestinal propulsion movement of normal mice and enhance the intestinal peristalsis. Poria is a dry sclerotium of Polyporaceae fungus Poria penia cocos (Schw.) Wolf, a clinically usual traditional Chinese medicine, according to the description of Ben Cao gang: poria cocos has sweet, light and flat taste, and can restore heart, lung, spleen and kidney meridians, thereby being beneficial to the effects of promoting diuresis, removing dampness, strengthening spleen and calming heart; modern researches have shown that polysaccharides, triterpenes and pachymic acid in Poria can improve gastrointestinal symptoms by anti-inflammatory, gastrointestinal motility and intestinal microecology. The pericarpium Citri Tangerinae extract and Poria extract refer to active ingredients extracted from pericarpium Citri Tangerinae and Poria, and can be extracted or purchased according to conventional technical means in the art. Based on the dried orange peel extract and the poria cocos extract contained in the raw materials of the formula milk powder, the prepared formula milk powder is beneficial to promoting gastrointestinal peristalsis, improving gastrointestinal inflammation, relieving dyspepsia and repairing gastrointestinal mucosa injury, and especially has the effects of promoting gastrointestinal peristalsis and eliminating gastrointestinal inflammation, and has the function of regulating gastrointestinal tract; the tangerine peel extract and the Indian buead extract are medicinal and edible substances, have the characteristics of high safety, small side effect, strong efficacy, good taste and flavor and the like, exert the synergistic effect of regulating the gastrointestinal function to the greatest extent, do not contain Chinese medicinal material components, and avoid the influence of the Chinese medicinal materials on the taste and the flavor of the formula milk powder to the greatest extent.
Meanwhile, based on every 100g of formula milk powder, the content of protein in the formula milk powder is 16.5-30 g, the content of fat is 1.0-23 g, the content of dietary fiber is 0-7.5 g, and the content of carbohydrate is 50-69 g. The content of protein, fat, dietary fiber and carbohydrate can be determined by testing by conventional means in the art; for example, the protein and fat content can be measured according to GB 5009; the content of dietary fiber can be detected according to GB/T22224; carbohydrates may be calculated according to GB 28050.
Further, based on 1000 parts by mass of formula milk powder, the mass parts of the dried orange peel extract in the raw materials for preparing the formula milk powder are 4-20, and the mass parts of the poria cocos extract are 8-20; for example, the dried orange peel extract is prepared in parts by mass of one of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 parts by mass per 1000 parts by mass of the formula milk powder, and the poria cocos is prepared in parts by mass of one of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 parts by mass.
In one embodiment, in order to improve the synergistic effect of the dried orange peel extract and the poria cocos extract, the mass ratio of the dried orange peel extract to the poria cocos extract is 1 (1-2).
In one embodiment, the composition for regulating gastrointestinal function further comprises a plant extract which is used in food, in addition to the dried orange peel extract and the poria extract, wherein the plant extract is extracted or processed by using a proper solvent or method by taking plants (all or a part of plants) as raw materials. Specifically, the composition with gastrointestinal tract regulating function also comprises Hericium erinaceus extract. Hericium erinaceus contains abundant minerals, vitamins, unsaturated fatty acids and polysaccharides. According to the description in Ben Cao gang mu: hericium erinaceus is flat in nature and sweet in taste; the five viscera are benefited, and digestion is promoted; has effects of invigorating spleen, invigorating stomach, and treating asthenia. Clinical experiments show that the hericium erinaceus has the effects of protecting gastric mucosa, improving cellular immunity, resisting helicobacter pylori, preventing gastritis and the like.
Further, the mass parts of the hericium erinaceus extract in the raw materials for preparing the formula milk powder are 0-15 based on 1000 mass parts of the formula milk powder.
Further, the mass ratio of the dried orange peel extract to the tuckahoe extract to the hericium erinaceus extract is (0.5-2): 1.
In a specific embodiment, the composition with gastrointestinal tract regulating function further comprises wheat oligopeptide, wherein the wheat oligopeptide is wheat protein zymolyte and is a small molecular fragment obtained by hydrolyzing wheat protein (wheat gluten) with protease. The original nutritional value and physiological functions of the wheat protein are improved to different degrees by hydrolyzing the wheat protein with protease. The active ingredient glutamine in the wheat oligopeptide is a special nutrient substance for gastrointestinal mucosa cells. Under the stress state, glutamine is almost the only source of energy required by gastrointestinal mucosa metabolism, can improve intestinal immunity, reduce intestinal permeability and maintain intestinal mucosa structure to play a role in protecting gastrointestinal mucosa.
Further, the mass part of the wheat oligopeptide in the raw material for preparing the formula milk powder is 0-5 based on 1000 mass parts of the formula milk powder.
Further, the mass ratio of the tangerine peel extract, the poria cocos extract and the wheat oligopeptide is (4-16): (8-16): 1.
the dried orange peel extract, the poria cocos extract and the hericium erinaceus extract can be extracted by adopting a conventional technical means in the field or purchased from a commercial product; wheat oligopeptides can also be obtained by proteolytic digestion of wheat according to conventional techniques in the art, for example, by hydrolyzing wheat proteins using trypsin, neutral protease, immobilized alkaline protease, and the like.
In a specific embodiment, the raw materials for preparing the formula milk powder further comprise one or more of raw milk, whey protein powder, desalted whey powder and skimmed milk powder; raw milk, whey protein powder, desalted whey powder and skimmed milk powder are used as sources of protein and fat in the formula milk powder for providing basic nutritional ingredients, and can be specifically raw materials for preparing the formula milk powder, which are conventional in the art.
Further, based on 1000 parts by mass of the formula milk powder, the raw milk in the raw materials for preparing the formula milk powder is 0-3600 parts by mass, the skimmed milk powder is 25-500 parts by mass, and the desalted whey powder is 25-500 parts by mass.
In a specific embodiment, the raw materials for preparing the formula milk powder further comprise one or more of phospholipid, solid corn syrup, resistant dextrin and inulin. Further, the phospholipid is used as a source of fat in the formula milk powder, and the mass parts of the phospholipid in the raw materials for preparing the formula milk powder are 1-5 based on each 1000 mass parts of the formula milk powder. Further, the solid corn syrup is used as a source of carbohydrate in the formula, and the mass parts of the solid corn syrup in the raw materials for preparing the formula are 25-250 based on every 1000 mass parts of the formula. Further, the resistant dextrin and inulin are used as sources of dietary fibers in the formula, and the mass parts of the resistant dextrin in the raw materials for preparing the formula are 0-100 and the mass parts of the inulin are 0-50 based on every 1000 mass parts of the formula.
In a specific embodiment, the raw materials for preparing the formula milk powder further comprise one or more of galactooligosaccharide, isomerized lactose solution, milk mineral salt, lactoferrin, medlar powder, probiotics, calcium powder, vitamins and mineral compound nutrients. Further, in the raw materials for preparing the formula milk powder, based on every 1000 parts by mass of the formula milk powder, the weight parts of galacto-oligosaccharide are 0-20, and the weight parts of the isomerized lactose solution are 0-10; 1-5 parts by mass of milk mineral salt; 0-2 parts by mass of lactoferrin; the mass part of the medlar powder is 0-2; the mass part of the probiotics is 0-0.4; the weight portion of the nutrient containing calcium powder, vitamin and mineral is 7-22.
In a specific embodiment, the probiotic may be bifidobacteria. Further, the mass parts of bifidobacteria in the raw materials for preparing the formula milk powder are 0.1-0.4 based on each 1000 mass parts of the formula milk powder; and further 0.15 to 0.2 parts by mass. The bacterial activity of each mass part of bifidobacterium is 3 multiplied by 10 9 CFU or more.
In a specific embodiment, the nutrients comprising calcium powder, vitamins and minerals are a combination of nutrients meeting the national standards and are added in the form of calcium carbonate, vitamin packs, mineral nutrient packs. Specifically, each gram of vitamin nutrition package comprises vitamin A:1947-2477 μg RE; vitamin D3:36-46 μg; vitamin E:60-72mg alpha-TE; vitamin B6:4620-5880 μg; vitamin C:288-352mg.
Specifically, each gram of mineral nutrition package at least comprises 99-121mg of iron and 33-41mg of zinc.
Further, the raw materials for preparing the formula milk powder comprise 2-4 parts by mass of nutrients including calcium powder, vitamins and minerals per 1000 parts by mass of the formula milk powder.
The base material of each nutritional package is preferably lactose or sodium L-ascorbate.
The raw materials mainly comprise the raw materials of the formula milk powder, and the raw materials can be added according to the needs of a person skilled in the art, and the composition and the specific dosage of each raw material meet the national standard and related standards and regulations of the formula milk powder. In one embodiment, the raw materials for preparing the formula comprise 0-3600 parts by mass of raw milk, 25-500 parts by mass of skimmed milk powder, 25-250 parts by mass of solid corn syrup, 25-500 parts by mass of desalted whey powder, 0-100 parts by mass of resistant dextrin, 0-50 parts by mass of inulin, 0-20 parts by mass of galactooligosaccharide, 0-10 parts by mass of isomerized lactose solution, 0-5 parts by mass of milk mineral salt, 1-5 parts by mass of phospholipid, 7-22 parts by mass of nutrient containing calcium powder, vitamins and minerals, 2-50 parts by mass of dried orange peel extract, 2-50 parts by mass of poria cocos extract, 0-15 parts by mass of hericium erinaceus extract, 0-5 parts by mass of wheat oligopeptide, 0-2 parts by mass of medlar powder, 0-2 parts by mass of lactoferrin and 0-0.4 parts by mass of probiotics per 1000 parts by mass of formula milk powder.
The second aspect of the invention provides a preparation method of the formula milk powder, which comprises the following steps:
mixing the composition with gastrointestinal tract regulating function with the prepared formula milk powder, uniformly mixing, and sieving to obtain the formula milk powder;
the formula milk powder prefabricated material is powder obtained by mixing and sterilizing other raw materials of the formula milk powder.
In the preparation process of the formula milk powder, raw materials except the composition with the gastrointestinal tract regulating function in the formula milk powder are firstly mixed, homogenized, concentrated, sterilized and spray dried to prepare a formula milk powder prefabricated product, and then the composition with the gastrointestinal tract regulating function is added into the formula milk powder prefabricated product according to certain mass parts, and the formula milk powder is obtained after uniform mixing.
In a specific embodiment, taking a specific formula milk powder raw material provided in the first aspect of the present invention as an example, a preparation method of the formula milk powder is described in detail:
step 1, treating raw milk: preheating raw milk stored at 1-4deg.C by plate heat exchanger, centrifuging to remove micro solid and microorganism, and pulverizing large-particle fat globules by homogenizer to pasteurize.
And 2, weighing the skimmed milk powder, the solid corn syrup, the desalted whey powder, the resistant dextrin, the inulin and the milk mineral salt according to a formula, sterilizing, and then conveying the mixture to a powder preparation tank for mixing.
And 3, sucking the processed raw milk and the mixed materials in the powder preparation tank into a vacuum mixing tank, and mixing the raw milk and the mixed materials at 45+/-2 ℃ for 30-70 minutes to obtain the mixed materials with the concentration of 19-23%.
And 4, inputting the galactooligosaccharide, the isomerized lactose liquid and the phospholipid into a vacuum mixing tank according to certain mass parts, and mixing.
And 5, fully dissolving the nutrients comprising the calcium powder, the vitamins and the minerals for 5-30 minutes, and mixing the nutrient solution with the mixture in the vacuum mixing tank.
And 6, removing insoluble substances by using a filter, and homogenizing at 55-61 ℃ for 30-70min under 180-210bar total pressure.
And 7, inputting the homogenized feed liquid into a plate heat exchanger for cooling, wherein the cooling temperature is less than or equal to 7 ℃, the temporary storage temperature of the mixed materials is less than or equal to 8 ℃, and homogenizing is finished to a temporary storage tank.
Step 8, concentrating and sterilizing: preheating the mixed materials in the temporary storage tank to 44-52 ℃, and heating the mixed materials by steam injection to pasteurize at 89-92 ℃ and 5-8bar.
Step 9, cooling, filtering and evaporating: cooling the sterilized mixed material to room temperature, filtering impurities, and evaporating and concentrating in an evaporator to obtain concentrated milk with dry matter of 48-52%.
Step 10, spray drying: preheating concentrated milk to 67-73 ℃, carrying out duplex filtration on the preheated material, pressurizing and conveying the material to a drying tower by using a high-pressure pump, and spray drying by using a spray gun, wherein: the main air inlet temperature is 175-210 ℃, the air exhaust temperature is 80-93 ℃, and the negative pressure in the tower is-0.5 to-1.5 mbar.
Step 11, cooling and sieving: and (3) drying and cooling the milk powder discharged from the drying tower in a fluidized bed, and sieving the milk powder by a vibrating sieve, wherein the powder discharging temperature is less than or equal to 33 ℃.
And step 12, uniformly mixing the composition with the gastrointestinal tract regulating function, the medlar powder, the lactoferrin, the probiotics and the milk powder in a dry mixer according to the formula requirement.
And 13, passing the mixed materials through a vibrating screen to obtain the formula milk powder with uniform granularity, and scrapping the powder slag. Packaging the discharged formula milk powder, checking the finished product, and boxing.
The raw materials of the formula milk powder provided by the invention comprise the dried orange peel extract and the poria cocos extract, so that the prepared formula milk powder has the effects of promoting gastrointestinal peristalsis, improving gastrointestinal inflammation, relieving dyspepsia, repairing gastrointestinal mucosa injury, especially promoting gastrointestinal peristalsis and eliminating gastrointestinal inflammation, and has the effect of regulating gastrointestinal functions; in addition, the dried orange peel extract and the poria cocos extract are medicinal and edible substances, have the characteristics of high safety, small side effect, strong efficacy, good taste and flavor and the like, exert the synergistic effect of regulating the gastrointestinal function to the greatest extent, do not contain Chinese herbal medicine components, and avoid the influence of Chinese herbal medicine on the taste and flavor of the formula milk powder to the greatest extent.
Drawings
FIG. 1a is a graph showing the fluorescence intensity phenotype of the gastrointestinal tract after zebra fish treatment by the compositions provided in examples 1-3 and comparative examples 1-4;
FIG. 1b is a bar graph of the fluorescence intensity of the gastrointestinal tract after zebra fish treatment with the compositions provided in examples 1-3 and comparative examples 1-4;
FIG. 2a is a graph of gastrointestinal area phenotypes of the compositions provided in examples 1-5 and comparative examples 1-4, 7 after zebra fish treatment;
FIG. 2b is a bar graph of gastrointestinal area of the compositions provided in examples 1-5 and comparative examples 1-4, 7 after zebra fish treatment;
FIG. 3a is a graph of the gastrointestinal neutrophil count phenotype of the compositions provided in examples 4-5 and comparative examples 5-7 versus zebra fish treatment;
FIG. 3b is a bar graph of the number of neutrophils in the gastrointestinal tract versus zebra fish treatment provided by the compositions of examples 4-5 and comparative examples 5-7.
Detailed Description
For the purpose of making the objects, technical solutions and advantages of the present invention more apparent, the technical solutions in the embodiments of the present invention will be clearly and completely described in the following in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The components used in the following examples and comparative examples are commercially available products without particular emphasis.
Example 1
The composition provided in this example includes 20 parts by mass of dried orange peel extract and 20 parts by mass of poria cocos extract.
Example 2
The composition provided in this example includes 16 parts by mass of dried orange peel extract, 16 parts by mass of poria cocos extract and 8 parts by mass of hericium erinaceus extract.
Example 3
The composition provided in this example comprises 16 parts by mass of dried orange peel extract, 16 parts by mass of poria cocos extract and 1 part by mass of wheat oligopeptide.
Example 4
The composition provided in this example comprises 4 parts by mass of dried orange peel extract, 8 parts by mass of poria cocos extract and 1 part by mass of wheat oligopeptide.
Example 5
The composition provided in this example includes 8 parts by mass of dried orange peel extract and 12 parts by mass of poria cocos extract.
Comparative example 1
The composition provided in this comparative example was 40 parts by mass of a Hericium erinaceus extract.
Comparative example 2
The composition provided in this comparative example was 72 parts by mass of Poria cocos extract.
Comparative example 3
The composition provided in this comparative example was 36 parts by mass of dried orange peel extract.
Comparative example 4
The composition provided in this comparative example was 36 parts by mass of wheat oligopeptide.
Comparative example 5
The composition provided in this comparative example was 18 parts by mass of Poria cocos extract.
Comparative example 6
The composition provided in this comparative example was 18 parts by mass of dried orange peel extract.
Comparative example 7
The composition provided in this comparative example was 13 parts by mass of wheat oligopeptide.
Experimental example 1 evaluation of gastrointestinal motility improving efficacy
1. Experimental sample
The compositions provided in examples 1-3 and comparative examples 1-4.
Positive control: and (3) moldines (domperidone tablets), white tablets, lot number 190104499, and xian yansen pharmaceutical limited company, and storing in shade. Stock solution of 10.0mg/mL was prepared with DMSO and stored at-20 ℃.
2. Experimental animal
Wild type AB strain zebra fish: is carried out in a natural paired mating propagation mode. Zebra fish aged 3 days post fertilization (3 dpf) were 30 tails per experimental group.
The zebra fish is all cultivated in water with a temperature of 28deg.C (water quality: 200mg instant sea salt is added into 1L reverse osmosis water, conductivity is 450-550 μS/cm, pH is 6.5-8.5, and hardness is 50-100mg/L CaCO) 3 ) Is provided by the breeding center of Hangzhou Cyclothe biotechnology limited company, and the breeding management meets the requirements of international AAALAC authentication.
3. Instrument and reagent
Dissecting microscope (SZX 7, OLYMPUS, japan); CCD camera (VertA 1, shanghai Tusen Vision technologies Co., ltd.); electrokinetically focused continuously variable magnification fluorescence microscope (AZ 100, nikon, japan); precision electronic balances (CP 214, OHAUS, USA); 6-well plates (Nest Biotech, china); dimethyl sulfoxide (DMSO, lot BCCD8942, sigma, switzerland); trinitrobenzenesulfonic acid (TNBS, lot SLCK4178, sigma, USA); methylcellulose (lot number C2004046, china, gladine biochemical technologies inc.); nile red (lot number SLBP9326V, sigma, india).
4. Experimental method
Gastrointestinal motility improvement efficacy experiment: 3dpf wild type AB strain zebra fish were randomly selected in 6-well plates, and 30 zebra fish were treated per well (experimental group). Each of the remaining experimental groups, except the normal control group, was given TNBS in a water-soluble manner to establish a zebra fish dyspepsia model. After 2 days of treatment at 28 ℃, TNBS was removed and nile red was given as a fluorescent indicator of intestinal content in water-soluble form. Zebra fish were randomly distributed into 6-well plates after feeding, and 30 zebra fish were treated per well (experimental group). The administration treatments were performed in accordance with the administration dose concentrations of the comparative example and the example, and the normal control group and the model control group were simultaneously set to have a capacity of 3mL per well. And processing at 28 ℃ to 7dpf, taking pictures under a fluorescence microscope from 10 zebra fish selected randomly from each group, storing pictures, analyzing and collecting data by using NIS-Elements D3.20 advanced image processing software, analyzing the gastrointestinal tract fluorescence intensity (S) of the zebra fish, and evaluating the gastrointestinal tract power improvement effect of the sample according to the index statistical analysis result.
In the gastrointestinal motility efficacy study, zebra fish are fed with specific fluorescent dyes which cannot be absorbed by the gastrointestinal tract, and the slower the gastrointestinal motility of the zebra fish, the stronger the fluorescent dye intensity in the zebra fish. The experimental results are shown in FIGS. 1a-1b and Table 1, the fluorescence intensity in the zebra fish gastrointestinal tract in examples 1-3 and comparative example 3 is significantly reduced (P < 0.001) compared to the model control, and the fluorescence intensity in the zebra fish gastrointestinal tract in examples 1-3 is weaker than that in comparative examples 1-2 and comparative example 4. The fluorescence intensity in the zebra fish gastrointestinal tract in comparative example 3 is the weakest, which shows that the effect of singly relieving gastrointestinal motility of the dried orange peel extract is more prominent, but the cost of the dried orange peel extract is higher, the price of the dried orange peel extract is equivalent to that of the hericium erinaceus extract, and is 1.6-2 times of the price of the poria cocos extract and the wheat oligopeptide.
TABLE 1 gastrointestinal motility improvement experimental results for the compositions provided in examples 1-3 and comparative examples 1-4
| Group of | Zebra fish intervention dose (mug/mL) | Gastrointestinal fluorescence intensity (pixel) |
| Normal control group | / | 294378±6668*** |
| Model control group | / | 496239±20206 |
| Positive control (Mortidine) | 87.5 | 236246±11278*** |
| Example 1 | 139+139 | 348646±11407*** |
| Example 2 | 111+111+55.6 | 328188±19960*** |
| Example 3 | 111+111+6.94 | 319828±7342*** |
| Comparative example 1 | 278 | 449907±29253 |
| Comparative example 2 | 500 | 430599±22388 |
| Comparative example 3 | 250 | 305609±10330*** |
| Comparative example 4 | 250 | 387509±11942** |
Wherein P < 0.01 and P < 0.001.
Experimental example 2 evaluation of efficacy of repair of gastrointestinal mucosal injury
1. Experimental sample
Samples prepared in examples 1-5 and comparative examples 1-4, 7
Positive control: prednisone, white powder, lot number C10016501, shanghai Milin Biochemical technologies Co., ltd., stored at 4 ℃. Stock solution (15.0 mg/mL) was prepared with DMSO and stored at-20deg.C.
2. Experimental animal
The same as in experimental example 1.
3. Instrument and reagent
The same as in experimental example 1.
4. Experimental method
Evaluation of gastrointestinal mucosal injury repair efficacy: 3dpf wild type AB strain zebra fish were randomly selected in 6-well plates, and 30 zebra fish were treated per well (experimental group). Each experimental group except the normal control group was given TNBS in a water-soluble manner to establish a zebra fish gastrointestinal mucosa injury model. After 2 days of treatment at 28 ℃, TNBS was removed and 30 zebra fish were treated per well (experimental group). The administration treatments were performed in accordance with the administration dose concentrations of the comparative example and the example, and the normal control group and the model control group were simultaneously set to have a capacity of 3mL per well. After the treatment is continued for 2 days at 28 ℃, 10 zebra fish are randomly selected from each experimental group, photographed under an dissecting microscope, data are collected by using NIS-Elements D3.20 advanced image processing software, the gastrointestinal tract area (A) of the zebra fish is analyzed, and the gastrointestinal mucosa injury repair efficacy of the sample is evaluated according to the statistical analysis result of the index.
5. Experimental results
In the evaluation of gastrointestinal mucosal lesion repair efficacy, TNBS may disrupt the gastrointestinal mucosal barrier, bind to intestinal tissue proteins to form antigens, develop allergies, and induce ulcerative gastrointestinal lesions. Lesions in the gastrointestinal tract involve muscle layers and nerves, resulting in hypotonia of the gastrointestinal wall and enlargement of the gastrointestinal lumen. By analyzing the gastrointestinal area, the improvement effect of the test sample on the gastrointestinal mucosa injury can be evaluated. The experimental results are shown in FIGS. 2a-2b and Table 2, and it can be seen that examples 1-5 have significantly reduced gastrointestinal area (P < 0.001) compared to the model group. Among them, examples 1-2 have a synergistic effect compared with comparative examples 1-3, and the gastrointestinal mucosa repair rate is superior to comparative examples 1-3. Although comparative example 4 works best in gastrointestinal mucosal repair, low dose composition development presents its advantages because the bitter taste of wheat oligopeptide itself limits its use in products. Examples 4-5 are synergistic at lower doses, and the two compositions are significantly better than comparative example 2, with no significant difference compared to comparative examples 3, 7.
TABLE 2 results of experiments on repair of gastrointestinal mucosal lesions of compositions provided in examples 1-5 and comparative examples 1-4, 7
Wherein P < 0.001.
Experimental example 3 evaluation of efficacy of resolution of gastrointestinal inflammation
1. Experimental sample
The compositions provided in examples 4-5 and comparative examples 5-7.
Positive control: prednisone, white powder, lot number C10016501, shanghai Milin Biochemical technologies Co., ltd., stored at 4 ℃. Stock solution (15.0 mg/mL) was prepared with DMSO and stored at-20deg.C.
2. Experimental animal
Transgenic neutrophil fluorescent zebra fish (MPX): zebra fish of the age 3dpf after fertilization.
3. Instrument and reagent
The same as in experimental example 1.
4. Experimental method
Gastrointestinal inflammation resolution efficacy experiment: the 3dpf transgenic neutrophil green fluorescent zebra fish were randomly selected in 6-well plates, and 30 zebra fish were treated in each well (experimental group). Each experimental group except the normal control group was given TNBS in a water-soluble manner to establish a zebra fish gastrointestinal mucosa injury model. After 2 days of treatment at 28 ℃, TNBS was removed and 30 zebra fish were treated per well (experimental group). The administration treatments were performed in accordance with the administration dose concentrations of the comparative example and the example, and the normal control group and the model control group were simultaneously set to have a capacity of 3mL per well. After further treatment at 28 ℃ for 2 days, 10 zebra fish were randomly selected from each experimental group, photographed under a fluorescence microscope, data were collected using NIS-Elements D3.20 advanced image processing software, the number of zebra fish gastrointestinal neutrophils (N) was analyzed, and the efficacy of the regression of gastrointestinal inflammation of the sample was evaluated using the statistical analysis result of the index.
5. Experimental results
Inflammatory reaction occurs during gastrointestinal tract pathological changes, neutrophils are recruited to the damaged part, and the phenomenon of neutrophil number increase occurs. The experimental results are shown in FIGS. 3a-3b and Table 3, and it can be seen that the numbers of neutrophils in the gastrointestinal tract after treatment of both the examples and the comparative examples are significantly reduced (P < 0.001) compared with the model control group, and the gastrointestinal inflammation improving effect of the examples is improved compared with the comparative examples.
TABLE 3 gastrointestinal inflammation resolution efficacy experimental results for the compositions provided in examples 4-5 and comparative examples 5-7
| Zebra fish intervention dose(μg/mL) | Gastrointestinal neutrophil count (mean ± SE) | |
| Normal control group | / | 7.70±0.396*** |
| Model control group | / | 18.8±0.359 |
| Positive control (prednisone) | 15.0 | 8.80±0.442*** |
| Example 4 | 27.8+55.6+6.94 | 8.40±0.306*** |
| Example 5 | 55.6+83.3 | 6.8±0.490*** |
| Comparative example 5 | 125 | 11.9±0.567*** |
| Comparative example 6 | 125 | 11.0±0.615*** |
| Comparative example 7 | 90.3 | 11.2±0.629*** |
Wherein P < 0.001.
Example 6
Based on the composition with gastrointestinal tract regulating function provided in example 5, the raw materials of the formula milk powder provided in this example include: 3000 parts of raw milk, 175 parts of skim milk powder, 200 parts of solid corn syrup, 225 parts of desalted whey powder, 10 parts of galactooligosaccharide, 7 parts of isomerized lactose solution, 4 parts of milk mineral salt, 2 parts of phospholipid, 16 parts of calcium powder, 2.5 parts of vitamin package, 1 part of mineral nutrient package, 6.67 parts of dried orange peel extract, 10.01 parts of poria cocos extract, 1.2 parts of medlar powder, 1 part of lactoferrin and 0.22 part of bifidobacterium.
The raw materials are mixed according to a certain proportion and prepared into the formula milk powder, wherein the protein content is 17.1g/100g, the fat content is 11.1g/100g, the carbohydrate content is 63.8g/100g, and the dietary fiber content is 0g/100g.
Example 7
Based on the composition with gastrointestinal tract regulating function provided in example 2, the raw materials of the formula milk powder provided in this example include: 3400 parts of raw milk, 150 parts of skim milk powder, 225 parts of solid corn syrup, 200 parts of desalted whey powder, 2 parts of phospholipid, 16 parts of calcium powder, 2.5 parts of vitamin package, 3.5 parts of mineral nutrient package, 14 parts of dried orange peel extract, 14 parts of poria cocos extract, 7 parts of hericium erinaceus extract and 0.155 part of bifidobacterium.
The raw materials are mixed according to a certain proportion and prepared into the formula milk powder, wherein the protein content is 17.1g/100g, the fat content is 12.4g/100g, the carbohydrate content is 62.5g/100g and the dietary fiber content is 0g/100g.
Example 8
Based on the composition with gastrointestinal tract regulating function provided in example 4, the raw materials of the formula milk powder provided in this example include: 425 parts of skim milk powder, 175 parts of solid corn syrup, 352 parts of desalted whey powder, 50 parts of resistant dextrin, 10 parts of inulin, 5 parts of milk mineral salt, 2 parts of phospholipid, 16 parts of calcium powder, 2.5 parts of vitamin package, 3.5 parts of mineral nutrient package, 3.5 parts of dried orange peel extract, 7 parts of poria cocos extract, 0.875 part of wheat oligopeptide and 0.155 part of bifidobacterium.
The raw materials are mixed according to a certain proportion and prepared into the formula milk powder, wherein the protein content is 17.6g/100g, the fat content is 1.0g/100g, the carbohydrate content is 68.1g/100g and the dietary fiber content is 5g/100g.
The composition with gastrointestinal function regulation function provided by examples 2, 4 and 5, and the formula milk powder comprising the composition also has the effect of gastrointestinal function regulation, and has the characteristics of high safety, small side effect, strong efficacy, good taste and flavor and the like.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention, and not for limiting the same; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some or all of the technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit of the invention.
Claims (10)
1. A formula milk powder with gastrointestinal tract regulating function, which is characterized in that the raw materials for preparing the formula milk powder at least comprise a composition with gastrointestinal tract regulating function, and the composition with gastrointestinal tract regulating function at least comprises a dried orange peel extract and a poria cocos extract;
based on 1000 parts by mass of formula milk powder, the mass parts of the dried orange peel extract in the raw materials for preparing the formula milk powder are 2-50, and the mass parts of the poria cocos extract are 2-50;
based on every 100g of the formula milk powder, the content of protein in the formula milk powder is 16.5-30 g, the content of fat is 1.0-23 g, the content of dietary fiber is 0-7.5 g, and the content of carbohydrate is 50-69 g.
2. The formula milk powder according to claim 1, wherein the mass ratio of the dried orange peel extract to the poria cocos extract is 1 (1-2).
3. The formula according to claim 1 or 2, wherein the composition having gastrointestinal tract regulating function further comprises a hericium erinaceus extract;
and/or, based on 1000 parts by mass of the formula milk powder, the mass parts of the hericium erinaceus extract in the raw materials for preparing the formula milk powder are 0-15.
4. A formula milk powder according to claim 3, wherein the mass ratio of the dried orange peel extract, the poria cocos extract and the hericium erinaceus extract is (0.5-2): 1.
5. The formula according to any one of claims 1 to 4, wherein the composition with gastrointestinal tract modulating function further comprises wheat oligopeptide;
and/or, based on 1000 parts by mass of the formula milk powder, the mass part of the wheat oligopeptide in the raw material for preparing the formula milk powder is 0-5.
6. The formula milk powder according to claim 5, wherein the mass ratio of the dried orange peel extract, the poria cocos extract and the wheat oligopeptide is (4-16): (8-16): 1.
7. the formula milk powder according to any one of claims 1 to 6, wherein the raw materials for preparing the formula milk powder further comprise one or more of raw milk, whey protein powder, desalted whey powder and skimmed milk powder;
and/or, based on 1000 parts by mass of the formula milk powder, the raw milk in the raw materials for preparing the formula milk powder is 0-3600 parts by mass, the skimmed milk powder is 25-500 parts by mass, and the desalted whey powder is 25-500 parts by mass.
8. The formula according to any one of claims 1-7, wherein the raw materials for preparing the formula further comprise one or more of phospholipids, solid corn syrup, resistant dextrin, inulin, galacto-oligosaccharides, isomerized lactose solution, milk mineral salts, lactoferrin, matrimony vine powder, probiotics, calcium powder, vitamins and minerals;
and/or, based on every 1000 parts by mass of the formula milk powder, the mass part of phospholipids in the raw materials for preparing the formula milk powder is 1-5, the mass part of solid corn syrup is 25-250, the mass part of resistant dextrin is 0-100, the mass part of inulin is 0-50, the mass part of galacto-oligosaccharide is 0-20, and the mass part of isomerized lactose solution is 0-10; 1-5 parts by mass of milk mineral salt; 0-2 parts by mass of lactoferrin; the mass part of the medlar powder is 0-2; the mass part of the probiotics is 0-0.4; the weight portion of the nutrient containing calcium powder, vitamin and mineral is 7-22.
9. The formula according to any one of claims 1 to 8, wherein the raw materials for preparing the formula comprise 0 to 3600 parts by mass of raw milk, 25 to 500 parts by mass of skim milk powder, 25 to 250 parts by mass of solid corn syrup, 25 to 500 parts by mass of desalted whey powder, 0 to 100 parts by mass of resistant dextrin, 0 to 50 parts by mass of inulin, 0 to 20 parts by mass of galacto-oligosaccharide, 0 to 10 parts by mass of isomerized lactose solution, 0 to 5 parts by mass of milk mineral salt, 1 to 5 parts by mass of phospholipids, 7 to 22 parts by mass of nutrients including calcium powder, vitamins and minerals, 2 to 50 parts by mass of dried orange peel extract, 2 to 50 parts by mass of poria cocos extract, 0 to 15 parts by mass of hericium erinaceus extract, 0 to 5 parts by mass of wheat oligopeptide, 0 to 2 parts by mass of medlar powder, 0 to 2 parts by mass of lactoferrin, and 0 to 0.4 parts by mass of probiotics per 1000 parts by mass of formula.
10. A method of preparing a formula as claimed in any one of claims 1 to 9, comprising the steps of:
mixing the composition with gastrointestinal tract regulating function with the prepared formula milk powder, uniformly mixing, and sieving to obtain the formula milk powder;
the formula milk powder prefabricated material is powder obtained by mixing and sterilizing other raw materials of the formula milk powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311445555.2A CN117426422A (en) | 2023-11-01 | 2023-11-01 | Formula milk powder with gastrointestinal tract regulating function and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311445555.2A CN117426422A (en) | 2023-11-01 | 2023-11-01 | Formula milk powder with gastrointestinal tract regulating function and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117426422A true CN117426422A (en) | 2024-01-23 |
Family
ID=89558061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311445555.2A Pending CN117426422A (en) | 2023-11-01 | 2023-11-01 | Formula milk powder with gastrointestinal tract regulating function and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117426422A (en) |
-
2023
- 2023-11-01 CN CN202311445555.2A patent/CN117426422A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6869621B2 (en) | Diet composition comprising raw foods and dietary fibers | |
| CN101415342B (en) | Composition for beverage or food | |
| CN107319525A (en) | One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof | |
| US20040253227A1 (en) | Perioperative multivitamin protein beverage and additive for use in preparing an individual for fast surgical recovery | |
| KR101539382B1 (en) | Food composition for improvement of bowel function and relief of constipation | |
| US20040253295A1 (en) | Perioperative multivitamin protein bar for use in preparing an individual for fast surgical recovery | |
| KR101687982B1 (en) | Composition for improving sexual functionality having effects of increasing of the number of sperm and protection of environmental hormone and manufacturing method thereof | |
| CN107348521A (en) | With compound peptide combinations of Chinese medicine for improving gastrointestinal function and preparation method thereof | |
| CN108703365A (en) | Protein allergy tailored version clinical nutrition formula and preparation method thereof | |
| CN1669478A (en) | Preparation method of vinegar-egg powder, compound containing vinegar-egg powder and application thereof | |
| CN106036898A (en) | Composition having anti-fatigue effects and preparation method and use thereof | |
| CN103340291A (en) | Chinese herbal feed modifier for improving meat quality of livestock and poultry and quality of fresh eggs | |
| KR101100337B1 (en) | Manufacturing method of granular tea using Phellinus linteus | |
| US9737583B2 (en) | Composition for prevention or treatment of acute renal failure including herbal extract or fraction thereof as active ingredient | |
| KR0180452B1 (en) | Nutritious composition which can relieve constipation and remove bad smell of feces | |
| CN117426422A (en) | Formula milk powder with gastrointestinal tract regulating function and preparation method thereof | |
| KR100902947B1 (en) | Composition Containing Culture of Bacillus subtilis MORI for Growth Promotion | |
| JP2006511504A (en) | Pharmaceuticals for use as therapeutics | |
| CN112472733B (en) | A flos Puerariae Lobatae extract for promoting calcium oral absorption | |
| KR101908850B1 (en) | Medicinal-Herb Composition Comprising Chinese matrimony vine for Anti-Obesity and the Method of Making the Same | |
| CN112655802A (en) | Calcium gel candy and preparation process thereof | |
| CN105902760B (en) | A kind of Chinese medicine for treating rabbit stomach enteritis | |
| KR20200120549A (en) | Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale | |
| KR100899556B1 (en) | Functional Foods Adding Sargassum spp. Extracts | |
| DE60037197T2 (en) | USE OF FUNCTIONAL ORAL PREPARATIONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |